Workflow
Daré Bioscience(DARE) - 2024 Q3 - Quarterly Results
DAREDaré Bioscience(DARE)2024-11-14 21:10

Financial Performance - Total revenue for the three months ended September 30, 2024, was 41,691,adecreasefrom41,691, a decrease from 1,000,000 in the same period of 2023, representing a decline of 95.8%[28] - Operating expenses for the same period were 4,723,040,downfrom4,723,040, down from 9,396,415 in the prior year, indicating a reduction of 49.7%[28] - Net loss for the three months ended September 30, 2024, was 4,702,501,comparedtoanetlossof4,702,501, compared to a net loss of 8,299,096 in the same period of 2023, reflecting an improvement of 43.5%[28] Cash and Assets - Daré Bioscience reported cash and cash equivalents of 11.2millionasofSeptember30,2024[11]−CashandcashequivalentsasofSeptember30,2024,were11.2 million as of September 30, 2024[11] - Cash and cash equivalents as of September 30, 2024, were 11,232,609, an increase from 10,476,056attheendof2023[29]−Workingcapitalimprovedto10,476,056 at the end of 2023[29] - Working capital improved to 1,790,546 as of September 30, 2024, compared to a deficit of 2,936,897attheendof2023[29]−Totalassetsdecreasedto2,936,897 at the end of 2023[29] - Total assets decreased to 18,058,801 as of September 30, 2024, down from 21,282,215attheendof2023,adeclineof15.521,282,215 at the end of 2023, a decline of 15.5%[29] - Total stockholders' deficit improved to (1,484,483) as of September 30, 2024, compared to (5,047,640)attheendof2023,indicatingareductionof70.7(5,047,640) at the end of 2023, indicating a reduction of 70.7%[29] Research and Development - Research and development expenses were 2.7 million in Q3 2024, a 60% decrease from 6.7millioninQ32023,mainlyduetothecompletionofthePhase2bRESPONDclinicalstudyforSildenafilCream[13]−TheplannedPhase3studyofSildenafilCream,3.66.7 million in Q3 2023, mainly due to the completion of the Phase 2b RESPOND clinical study for Sildenafil Cream[13] - The planned Phase 3 study of Sildenafil Cream, 3.6% is expected to cost approximately 15 million in direct costs, with two successful studies required for NDA submission[10] - Daré is advancing the Phase 3 study of Ovaprene®, with recruitment currently at 10 sites across the U.S., aiming for 125 women to complete the study by mid-2025[9] - The company is preparing for a Phase 2 clinical study of DARE-VVA1 and a Phase 1 study of DARE-PTB1, the latter supported by a 2milliongrantfromNICHD[5]GrantsandFunding−Thecompanyreceiveda2 million grant from NICHD[5] Grants and Funding - The company received a 10 million award from ARPA-H for the DARE-HPV program, aimed at treating HPV-related cervical diseases[3] - A foundation grant of approximately 10.7millionwasannouncedtofundthedevelopmentofanovelnon−hormonalintravaginalcontraceptiveproductcandidateandtoexpandclinicalsitesfortheongoingOvaprene®pivotalstudy[1]−Thecompanyexpectstoreceive10.7 million was announced to fund the development of a novel non-hormonal intravaginal contraceptive product candidate and to expand clinical sites for the ongoing Ovaprene® pivotal study[1] - The company expects to receive 10 million in funding under ARPA-H's Sprint for Women's Health initiative[27] - Daré anticipates accessing $15 million in additional capital under its equity line arrangement with Lincoln Park Capital Fund[27] Product Development and Focus - Daré's first FDA-approved product, XACIATO™, is a treatment for bacterial vaginosis and is available by prescription nationwide[5] - The company aims to deliver innovative treatments that prioritize women's health and well-being, focusing on areas such as contraception and sexual health[23]